SAN DIEGO, Dec. 07, 2016 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in Pennsylvania on behalf of certain purchasers of shares of Lannett Company, Inc. (NYSE:LCI) over alleged Securities Laws Violations by Lannett Company.
Investors, who purchased shares of Lannett Company, Inc. (NYSE:LCI) in August 2013 or earlier and currently hold any of those NYSE:LCI shares, have also certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff alleges that the defendants made allegedly false and/or misleading statements and/or failed to disclose that Lannett Company, Inc. was fixing, maintaining, and controlling prices of digoxin in violation of Connecticut antitrust laws, that Lannett Company, Inc. was allocating and dividing customers and territories with competitors relating to the sale of digoxin in violation of Connecticut antitrust laws, that Lannett Company, Inc.’s anticompetitive practices subjected Lannett to heightened regulatory scrutiny, including possible investigation by the Connecticut Office of the Attorney General ("CTAG"), and that as a result of the foregoing, Lannett Company, Inc.'s public statements were allegedly materially false and misleading at all relevant times.
Those who purchased Lannett Company, Inc. (NYSE:LCI) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
[email protected]
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108


Washington Post Publisher Will Lewis Steps Down After Layoffs
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Instagram Outage Disrupts Thousands of U.S. Users
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 



